| abstract |
The present invention provides compositions and methods for treating or preventing diseases or disorders using SHP2 inhibitors alone and in combination with other therapeutic agents such as RAS pathway inhibitors ( for example MEK inhibitors); methods for establishing appropriate treatment plans for patients based on the expression of one or more biomarkers indicative of sensitivity to the SHP2 inhibitor; and methods for determining sensitivity to an inhibitor of SHP2 based on the phosphorylation state of SHP2. |